JPMorgan Starts Luminex (LMNX) at Neutral
More News related to LMNX
- Cowen & Co Initiates Coverage on Luminex (LMNX) with a Neutral; Upside Potential, But Reflected In Premium Valuation
- Matrix USA Rating Changes 10/08
- Luminex (LMNX) Receives Clearance from Health Canada for its xTAG Respiratory Viral Panel
- Luminex Corporation Receives Clearance from Health Canada for xTAG(TM) Respiratory Viral Panel
- SQI Diagnostics Announces Appointment of Senior VP, Sales and Marketing
More News related to New Coverage
- Brean Murray Downgrades Coherent (COHR) to Hold
- Goldman Sachs Dowgnrades Arkansas Best (ABFS) to Sell
- Jefferies Downgrades Monotype Imaging (TYPE) to Hold
- Wachovia Downgrades FelCor (FCH) and Hersha (HT) to Underperform
- Citi Downgrades Westar Energy (WR) to Hold
JPMorgan initiates coverage on Luminex Corporation (Nasdaq: LMNX) with a Neutral rating.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for applications in the life sciences industry.
Related Categories
New CoverageStocks Mentioned
-0.09Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
